Private Wealth Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Private Wealth Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3K	Hold	41	–	–	﹤0.01%	682
2026 Q1	$13.6K	Sell	41 -1	-2%	-$340	﹤0.01%	641
2025 Q4	$16.7K	Hold	42	–	–	﹤0.01%	585
2025 Q3	$19.2K	Hold	42	–	–	﹤0.01%	533
2025 Q2	$13.7K	Sell	42 -5	-11%	-$1.38K	﹤0.01%	598
2025 Q1	$12.7K	Buy	+47	New	+$12.1K	﹤0.01%	589

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Wealth Asset Management's ALNY Position: Q2 2026 in Review

Private Wealth Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 41 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #682.

Private Wealth Asset Management first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $19.2K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Private Wealth Asset Management held 41 shares of Alnylam Pharmaceuticals worth $12.3K as of Q2 2026.
Private Wealth Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Private Wealth Asset Management's portfolio in Q2 2026, its #682 holding.
Private Wealth Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Private Wealth Asset Management's Alnylam Pharmaceuticals position peaked at $19.2K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Private Wealth Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.